Funguria in Hospitalized Patients

Completed

• Conditions: Candidiasis

• Registration Number: NCT00138502
• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary

The purpose of the study is to test the hypothesis that a subpopulation of patients with candiduria are at significant risk for disseminated disease and would benefit from treatment, while others are at low risk from complications and therefore require no antifungal therapy.

Detailed Description

This protocol will attempt to generate a detailed clinical profile of patients with funguria and identify subgroups of patients with funguria at high risk for candiduria and determine the relative risks for obtaining candiduria. In addition, it will look at identifying subgroups of patients with funguria at high risk for candidemia and identifying subgroups of patients with funguria at high risk for death. Finally, it will attempt to determine if funguria independently predicts fungemia or death. Data will be complemented by surveillance of a comparable population without funguria.

Study Timeline

• Study Start: 2001-09-17
• Study First Submitted: 2005-08-26
• Study First Submitted QC: 2005-08-26
• Study First Posted: 2005-08-30
• Status Verified: 2007-10
• Primary Completion: 2008-12-08
• Study Completion: 2008-12-08
• Last Update Submitted: 2019-01-31
• Last Update Posted: 2019-02-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 926

Inclusion Criteria

1. Subjects with fungi isolated from the urine of any colony count.
2. Patients seen at either Harbor-UCLA Medical Center or Cedars Sinai Medical Center.

Exclusion Criteria

1. Persons with a previously positive urine fungal culture during the current hospital admission.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (2)

UCLA Center For Vaccine Research; 🇺🇸 Torrance, California, United States

Cedars Sinai Medical Center; 🇺🇸 Los Angeles, California, United States